This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diekema, D. J.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diekema, D. J.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1999, p. 940-943, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Comparison of Activities of Broad-Spectrum beta -Lactam Compounds against 1,128 Gram-Positive Cocci Recently Isolated in Cancer Treatment Centers

Daniel J. Diekema,1,* Stacy L. Coffman,1 Steven A. Marshall,1 Mondell L. Beach,1 Kenneth V. I. Rolston,2 and Ronald N. Jones1

Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa,1 and Section of Infectious Diseases, University of Texas, M.D. Anderson Cancer Center, Houston, Texas2

Received 19 October 1998/Returned for modification 10 December 1998/Accepted 13 January 1999

We report the in vitro activities of broad-spectrum beta -lactam antimicrobials tested against 1,128 gram-positive pathogens recently isolated from cancer patients. Cefepime and imipenem were more active than ceftazidime and ceftriaxone against these organisms. Only vancomycin demonstrated reliable activity against oxacillin-resistant staphylococci, Enterococcus spp., and Corynebacterium spp. The spectrum of gram-positive organisms against which cefepime and imipenem have activity provides an advantage over ceftazidime as empiric therapy for cancer patients, potentially reducing the need for the empiric addition of glycopeptides.

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 356-2990. Fax: (319) 356-4916. E-mail: daniel-diekema{at}uiowa.edu.

Antimicrobial Agents and Chemotherapy, April 1999, p. 940-943, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ashour, H. M., El-Sharif, A. (2007). Microbial Spectrum and Antibiotic Susceptibility Profile of Gram-Positive Aerobic Bacteria Isolated From Cancer Patients. JCO 25: 5763-5769 [Abstract] [Full Text]  
  • Paul, M., Borok, S., Fraser, A., Vidal, L., Leibovici, L. (2005). Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55: 436-444 [Abstract] [Full Text]  
  • Hufnagel, M., Hancock, L. E., Koch, S., Theilacker, C., Gilmore, M. S., Huebner, J. (2004). Serological and Genetic Diversity of Capsular Polysaccharides in Enterococcus faecalis. J. Clin. Microbiol. 42: 2548-2557 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»